Psychopharmacologic Drugs Advisory Committee Briefing Document; Zyprexa Olanzapine Pamoate (OP) Depot

February 6, 2008 Zyprexa is manufactured by Eli Lilly & Company as a treatment for schizophrenia and bipolar disorder. According to research presented to the U.S. Food and Drug Administration (FDA) Psychopharmacological Committee, about one percent of patients treated with the injectable version experienced excessive sedation as a side effect within three hours after the injection; two cases were described as comas. However, all patients recovered fully. This research was presented to the FDA Psychopharmacologic Drugs Advisory Committee, which said that the product appeared to be effective and acceptably safe . . .